-
公开(公告)号：US11471406B2
公开(公告)日：2022-10-18
申请号：US17063644
申请日：2020-10-05
Applicant: INTELGENX CORP.
Inventor： Nadine Paiement , Rodolphe Obeid , Justin Conway , Billal Tir
IPC: A61K9/00 , A61K47/38 , A61K31/4985
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.
-
公开(公告)号：US20190290595A1
公开(公告)日：2019-09-26
申请号：US16441872
申请日：2019-06-14
Applicant: Intelgenx Corp.
Inventor： Horst G. Zerbe , Rodolphe Obeid , Justin W. Conway , Nadine Paiement , Ludwig Aigner
IPC: A61K9/70 , A61K9/00 , A61K31/381 , A61K31/404 , A61K31/47
Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.
-
公开(公告)号：US20180228738A1
公开(公告)日：2018-08-16
申请号：US15912103
申请日：2018-03-05
Applicant: Intelgenx Corp.
Inventor： Horst G. Zerbe , Rodolphe Obeid , Justin W. Conway , Nadine Paiement , Ludwig Aigner
IPC: A61K9/70 , A61K31/47 , A61K31/381 , A61K31/404
Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.
-
公开(公告)号：US20170258710A1
公开(公告)日：2017-09-14
申请号：US15067309
申请日：2016-03-11
Applicant: Intelgenx Corp.
Inventor： Justin Conway , Rodolphe Obeid , Nadine Paiement , Horst Zerbe
Abstract: An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer.
-
公开(公告)号：US20170239172A1
公开(公告)日：2017-08-24
申请号：US15588897
申请日：2017-05-08
Applicant: Intelgenx Corp.
Inventor： Rodolphe Obeid , Nadine Paiement
Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
-
Patent Agency Ranking
公开(公告)号：US20170216220A1
公开(公告)日：2017-08-03
申请号：US15014269
申请日：2016-02-03
Applicant: Intelgenx Corp.
Inventor： Mobarik Bilal , Rodolphe Obeid , Nadine Paiement
CPC classification number: A61K9/7007 , A61K9/006 , A61K31/553 , A61K47/10 , A61K47/32 , A61K47/36
Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
-
公开(公告)号：US20230248660A1
公开(公告)日：2023-08-10
申请号：US18125800
申请日：2023-03-24
Applicant: Intelgenx Corp.
Inventor： Mobarik Bilal , Rodolphe Obeid , Nadine Paiement
IPC: A61K9/70 , A61K31/553 , A61K9/00 , A61K47/28 , A61K47/10 , A61K47/36 , A61K47/32 , A61K47/26 , A61K47/18 , A61K47/38
CPC classification number: A61K9/7015 , A61K31/553 , A61K9/006 , A61K47/28 , A61K47/10 , A61K47/36 , A61K47/32 , A61K47/26 , A61K47/186 , A61K9/7007 , A61K47/38
Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
-
公开(公告)号：US20200215063A1
公开(公告)日：2020-07-09
申请号：US16820794
申请日：2020-03-17
Applicant: Intelgenx Corp.
Inventor： Horst G. Zerbe , Nadine Paiement , Angela Angusti , Cormac Long , Rodolphe Obeid , Laetitia Rodes , Billal Tir
IPC: A61K31/4985 , A61K9/00 , A61K9/70
Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.
-
公开(公告)号：US20190247505A1
公开(公告)日：2019-08-15
申请号：US16391430
申请日：2019-04-23
Applicant: Intelgenx Corp.
Inventor： Nadine Paiement , Rodolphe Obeid , Billal Tir
IPC: A61K47/10 , A61K9/70 , A61K31/196 , A61K31/5513 , A61K9/00 , A61K31/4985 , A61K31/7076 , A61K31/704 , A61K31/60 , A61K31/58 , A61K31/573 , A61K31/5517 , A61K31/415 , A61K31/40 , A61K31/216
CPC classification number: A61K47/10 , A61K9/006 , A61K9/7007 , A61K31/196 , A61K31/216 , A61K31/40 , A61K31/415 , A61K31/4985 , A61K31/5513 , A61K31/5517 , A61K31/573 , A61K31/58 , A61K31/60 , A61K31/704 , A61K31/7076 , A61K38/00
Abstract: Oral thin film dosage form of a stable dispersion of non-solubilized amorphous or partially amorphous active agent(s), having a mean particle size diameter D50 equal or less than 250 μm, that remains uniformly distributed within a film matrix and contains at least one film forming polymer, and optional pharmaceutically-acceptable excipients, such as diluents, plasticizers, surfactants, sweeteners, and taste-masking agent(s), are prepared by a process including first providing the active agent in an amorphous particle form having a mean particle size diameter D50 equal or less than 250 μm. Next, the active agent is suspended in a liquid film-forming formulation without dissolving the active agent. Therefore, the solvent is removed to form a film.
-
公开(公告)号：US09668970B2
公开(公告)日：2017-06-06
申请号：US14554332
申请日：2014-11-26
Applicant: IntelGenx Corp.
Inventor： Rodolphe Obeid , Nadine Paiement
IPC: A61K47/32 , A61K9/00 , A61K31/09 , A61K31/155
CPC classification number: A61K9/006 , A61K31/09 , A61K31/155 , A61K47/32
Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.014 seconds)
